华贻军

华贻军，中山大学肿瘤防治中心肿瘤学博士，主任医师，硕士研究生导师，澳大利亚西悉尼大学访问学者。从事于鼻咽癌综合治疗的临床工作及相关转化研究，擅长复发鼻咽癌外科为主的综合治疗。于2011年受邀参与皇家澳大利亚新西兰放疗年会（RANZCR-ASM）并做主题发言。

主持和参与各级基金项目10余项。获国家专利授权4项；其中发明专利1项。

近年在The Lancet, JCO, Annals of Oncology, Journal for Immunotherapy of Cancer，Cell Disease and Differentiation，EJC，Aging(US)，Cell Disease & Death 等期刊发表SCI论文20余篇；

教育经历:

2010/09 - 2013/06    中山大学，肿瘤学博士

2003/09 - 2006/06    中山大学，临床肿瘤学硕士，硕士

1998/09 - 2003/06    华中科技大学同济医学院（同济医科大学），临床医学 

科研与学术工作经历：

2023/12-今              中山大学肿瘤防治中心，主任医师

2019/01 - 2023/12   中山大学肿瘤防治中心，副主任医师

2019/02 - 2019/12    云浮市人民医院副院长（挂职）  

2017/09 - 2017/11    澳大利亚Monash医学中心，参观学习

2013/09 - 2014/09    澳大利亚西悉尼大学，Ingham Institute，访问学者

2011/01 - 2018/12    中山大学肿瘤防治中心，主治医师 

2006/08 - 2010/12    中山大学肿瘤防治中心，住院医师 

四、专著

参编：《鼻咽癌诊断治疗》 世界图书出版广东有限公司，2012年11月出版 

五、主持或参加科研项目

1. 国家自然科学基金重点项目，82230034，：PALD1基因多态性调控血管内皮损伤促进放射性鼻咽坏死的作用及其机制研究，2023/01-2027/12，262万元，在研，参加（第2负责人）

2. 省企联合基金-面上项目，2021A1515220021，放化疗联合或不联合PD-1 单抗同时期及辅助维持治疗高危鼻咽癌的随机对照临床试验，2021.11.1-2024.10.31，20万元，在研，主持

3. 广东省省医学科学技术研究基金，A2019395，超分割调强放疗对比常规分割方式调强放疗治疗中晚期局部复发鼻咽癌的临床研究，2019.1-2021.1，1万元，在研，主持

4. 国家自然科学基金面上项目，81772895，p62/SQSTM1通过wnt/β-catenin通路促进鼻咽癌转移的分子机制，2018.1-2021.12，45万元，在研，参加

5. 国家自然科学基金面上项目，81572912，鼻咽癌远处转移分子标志物的筛选及其预测模型的构建，2015-2019，68.4万元，参加

6. 国家自然科学基金面上项目，81572901，自分泌胞外基质Serglycin上调其受体CD44以正反馈环方式维持鼻咽癌细胞干性，2015-2019，68.4万元，参加

7. 中山大学（中山医科大学）5010临床研究项目，2015011 ，超分割调强放疗对比传统分割方式调强放疗治疗局部复发鼻咽癌的多中心随机对照临床试验，2015-2017，20万元，结题，主持

8. 中山大学（中山医科大学）青年人才培育计划，11ykpy63 ，IGFBP-6/IGF-Ⅱ调控鼻咽癌转移的机制研究，2012-2014，15万元，已结题，参加

9. 国家自然科学基金面上项目，81071890，三维细胞培养模拟临床缺氧状态下HIF-1a转录调节Aurora激酶诱发鼻咽癌放疗抵抗的分子机制，2010-2013，33万元，已结题，参加

10. 校级中山大学（中山医科大学）青年人才培育计划，09ykpy50，经鼻内镜鼻咽切除术治疗rT2b期局部复发鼻咽癌中颈内动脉的暴露和保护，2010-2012，15万元，已结题，参加

11. 广东省省自然科学基金博士启动基金，8451008901000531，ApoG2靶向增强放射线诱导鼻咽癌细胞自噬死亡及其分子机制，2008-2010，3万元，已结题，参加

六、国际会议发言

October 7, 2011, in the RANZCR Melbourne 2011 Annual Scientific Meeting. In Melbourne, Australia.  Title: Delineation of the Target Volume for Advanced Nasopharyngeal Carcinoma after Induction Chemotherapy: Clinical Outcomes and Patterns of Failure

七、代表性研究成果和学术奖励情况

1. Liu YL, Wen K, Zhang WJ, Ouyang YF, Chen JH, Gu YK, Mei Q, Chen MY, Hua YJ^#， Li J. Assessment of Prophylactic Internal Carotid Artery Management in Postradiation Nasopharyngeal Necrosis Patients. Otolaryngol Head Neck Surg. 2024 Feb;170(2):447-456. doi: 10.1002/ohn.615. Epub 2023 Dec 17. PMID: 38104320.

2. You R, Liu YP, Xie YL, Lin C, Duan CY, Chen DP, Pan Y, Qi B, Zou X, Guo L, Cao JY, Zhang YN, Wang ZQ, Liu YL, Ouyang YF, Wen K, Yang Q, Xie RQ, Li HF, Duan XT, Ding X, Peng L, Chen SY, Liang JL, Feng ZK, Xia TL, Xie RL, Jiang R, Gu CM, Liu RZ, Sun R, Yang X, Liu LZ, Ling L, Liu Q, Ng WT, Hua YJ^#, Huang PY^# Chen MY^# Hyperfractionation compared with standard fractionation in intensity-modulated radiotherapy for patients with locally advanced recurrent nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial. Lancet. 2023 Feb 23:S0140-6736(23)00269-6. doi: 10.1016/S0140-6736(23)00269-6. Epub ahead of print. PMID: 36842439. (Co-corresponding)

3. Xi Ding, Wei-Jing Zhang, Rui You, Xiong Zou, Zhi-Qiang Wang, Yan-Feng Ouyang, Lan Peng, You-Ping Liu, Chong-Yang Duan, Qi Yang, Chao Lin, Yu-Long Xie, Si-Yuan Chen, Yong-Long Liu, Chen-Mei Gu, Ruo-Qi Xie, Pei-Yu Huang, Ming-Huang Hong^#, Yi-Jun Hua^#, Ming-Yuan Chen#. Camrelizumab Plus Apatinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma: An Open-Label, Single-Arm, Phase II Study. DOI: 10.1200/JCO.22.01450 Journal of Clinical Oncology. (Co-corresponding)

4. Hua YJ^#, Liu YL, Wen K, Kurts C, Wu H, Mei Q, Li J. Potentially improved response of COVID-19 vaccinated nasopharyngeal cancer patients to combination therapy with anti-PD-1 blockade and chemotherapy. Ann Oncol. 2022 Oct 7:S0923-7534(22)04188-6. doi: 10.1016/j.annonc.2022.10.002. Epub ahead of print. PMID: 36216192; PMCID: PMC9540702. (First author)

5. Hua Y, You R, Wang Z, Huang P, Lin M, Ouyang Y, Xie Y, Zou X, Liu Y, Duan C, Liu Y, Gu C, Liu R, Yang Q, Jiang R, Zhang M, Ding X, Chen S, Lin C, Sun R, Chen M. Toripalimab plus intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma: an open-label single-arm, phase II trial. J Immunother Cancer. 2021 Nov;9(11):e003290. doi: 10.1136/jitc-2021-003290. PMID: 34782428; PMCID: PMC8593727. (First author)

6. Hua YJ^#, Ou-Yang YF, Zou X, Xia L, Luo DH, Chen MY. The Effect of Prolonged Duration of Intensity Modulated Radiotherapy for Nasopharyngeal Carcinoma. Front Oncol. 2021 Sep 14;11:648637. doi: 10.3389/fonc.2021.648637. PMID: 34595104; PMCID: PMC8476902. (First author)

7. Lin M, Yang Q, You R, Zou X, Duan CY, Liu YP, Huang PY, Xie YL, Wang ZQ, Liu T, Chen SY, Hua YJ^#, Chen MY^#. Metastatic characteristics associated with survival of synchronous metastatic nasopharyngeal carcinoma in non-epidemic areas. Oral Oncol. 2021 Apr;115:105200. doi: 10.1016/j.oraloncology.2021.105200. Epub 2021 Feb 19. PMID: 33610003. (Co-corresponding)

8. Lin M, Yang Q, Zou X, You R, Duan CY, Liu YP, Huang PY, Xie YL, Wang ZQ, Liu T, Chen SY, Hua YJ^#, Chen MY^#. Biopsy of distant metastasis is not a significant prognostic factor for synchronous metastatic nasopharyngeal carcinoma: a propensity score-matched analysis from the Surveillance Epidemiology and End-Results Registry. J Cancer. 2021 May 27;12(14):4424-4432. doi: 10.7150/jca.54686. PMID: 34093843; PMCID: PMC8176419. (Co-corresponding)

9. Liao Y^#, Hua Y^#, Li Y^#, Zhang C, Yu W, Guo P, Zou K, Li W, Sun Y, Wang R, Zuo Y, Sui S, Tian C, Hao J, Chen M, Hu S, Chen M, Long Q, Wang X, Zou L, Xie F, Guo W, Deng W. CRSP8 promotes thyroid cancer progression by antagonizing IKKα-induced cell differentiation. Cell Death Differ. 2020 Nov 8. doi: 10.1038/s41418-020-00656-0. Epub ahead of print. PMID: 33162555.

10. Long Q^#, Hua Y^#, He L, Zhang C, Sui S, Li Y, Qiu H, Tian T, An X, Luo G, Yan Y, Zhao A, Shi D, Xie F, Chen M, Zheng F, Deng W. Poly(U) binding splicing factor 60 promotes renal cell carcinoma growth by transcriptionally upregulating telomerase reverse transcriptase. Int J Biol Sci. 2020 Sep 25;16(15):3002-3017. doi: 10.7150/ijbs.45115. PMID: 33061812; PMCID: PMC7545719.

11. Yu W^#, Hua Y^#, Qiu H, et al. PD-L1 promotes tumor growth and progression by activating WIP and β-catenin signaling pathways and predicts poor prognosis in lung cancer. Cell Death Dis. 2020;11(7):506. Published 2020 Jul 6. doi:10.1038/s41419-020-2701-z

12. Zhang C^#, Hua Y^#, Qiu H, et al. KMT2A regulates cervical cancer cell growth through targeting VDAC1. Aging (Albany NY). 2020;12(10):9604-9620. doi:10.18632/aging.103229

13. Wang ZQ, Mei Q, Li JB, You R, Sun R, Hu GR, Chen MY, Hua YJ. The long-term survival of patients with III-IVb stage nasopharyngeal carcinoma treated with IMRT with or without Nimotuzumab: a propensity score-matched analysis. BMC Cancer 19, 1122 (2019) doi:10.1186/s12885-019-6156-5 (Corresponding)

14. Zhao C^#, Miao JJ^#, Hua YJ^#, et al. Locoregional Control and Mild Late Toxicity After Reducing Target Volumes and Radiation Doses in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Treated With Induction Chemotherapy (IC) Followed by Concurrent Chemoradiotherapy: 10-Year Results of a Phase 2 Study. Int J Radiat Oncol Biol Phys. doi:10.1016/j.ijrobp.2019.03.043

15. You R^#, Hua YJ^#, Liu YP, et al. Concurrent Chemoradiotherapy with or without Anti-EGFR-Targeted Treatment for Stage II-IVb Nasopharyngeal Carcinoma: Retrospective Analysis with a Large Cohort and Long Follow-up. Theranostics. 2017 Jun 1;7(8):2314-2324. doi: 10.7150/thno.19710. eCollection 2017.

16. You R^#, Sun R^#, Hua YJ^#, Li CF, Li JB, Zou X, Yang Q, Liu YP, Zhang YN, Yu T, Cao JY, Zhang MX, Jiang R, Mo HY, Guo L, Cao KJ, Lin AH, Qian CN, Sun Y, Ma J, Chen MY. Cetuximab or nimotuzumab plus intensity-modulated radiotherapy versus cisplatin plus intensity-modulated radiotherapy for stage II-IVb nasopharyngeal carcinoma. Int J Cancer. 2017 Jun 2. doi: 10.1002/ijc.30819. [Epub ahead of print]

17. Hua YJ^#, Wang HY^#, Tang LQ, Chen QY, Shao JY*, Mai HQ*. LOX expression in primary nasopharyngeal carcinoma: correlation with prognostic parameters and outcome.Oncotarget. 2016 Jan 23. doi: 10.18632/oncotarget.6996. [Epub ahead of print]

18. Zhang MX, Hua YJ, Wang HY, Zhou L, Mai HQ, Guo X, Zhao C, Huang WL, Hong MH, Chen MY.  Long-term prognostic implications and therapeutic target role of hexokinase II in patients with nasopharyngeal carcinoma. Oncotarget. 2016 Feb 1. doi: 10.18632/oncotarget.7116. [Epub ahead of print]

19. Hu JL, Hua YJ, Chen Y, Yu B, Gao S. Structural analysis of tumor-related single amino acid mutations in human MxA protein. Chin J Cancer. 2015 Sep 28;34(3):55.

20. Hua YJ, Han F, Lu LX, Mai HQ, Guo X, Hong MH, Lu TX, Zhao C*. Long-term treatment outcome of recurrent nasopharyngeal carcinoma treated with salvage intensity modulated radiotherapy, Eur J Cancer. 2012，48(18): 3422-8 (in English)

21. You R, Zou X, Hua YJ, Han F, Li L, Zhao C, Hong MH, Chen MY. Salvage endoscopic nasopharyngectomy is superior to intensity-modulated radiation therapy for local recurrence of selected T1-T3 nasopharyngeal carcinoma - A case-matched comparison. Radiother Oncol. 2015 Jun;115(3):399-406.

22. Chen MY, Mai HQ, Sun R, Guo X, Zhao C, Hong MH, Hua YJ. Clinical findings and imaging features of 67 nasopharyngeal carcinoma patients with postradiation nasopharyngeal necrosis. Chin J Cancer. 2013，32(10): 533-8

23. Fu X, Hu J, Han HY, Hua YJ, Zhou L, Shuai WD, Du WY, Kuang CM, Chen S, Huang W, Liu RY. High expression of XPA confers poor prognosis for nasopharyngeal carcinoma patients treated with platinum-based chemoradiotherapy. Oncotarget. 2015 Sep 29;6(29):28478-90

24. Liang YY, Chen MY, Hua YJ, Chen S, Zheng LS, Cao X, Peng LX, Xie P, Huang BJ, Sun R, Wang L, Xiang YQ, Guo X, Qian CN.Downregulation of Ras Association Domain Family Member 6 (RASSF6) Underlies the Treatment Resistance of Highly Metastatic Nasopharyngeal Carcinoma Cells. PLoS One. 2014 Jul 16;9(7)

25. Lin HX, Hua YJ, Chen QY, Luo DH, Sun R, Qiu F, Mo HY, Mai HQ, Guo X, Xian LJ, Hong MH, Guo L.Randomized study of sinusoidal chronomodulated versus flat intermittent induction chemotherapy with cisplatin and 5-fluorouracil followed by traditional radiotherapy for locoregionally advanced nasopharyngeal carcinoma. Chin J Cancer. 2013;32(9):502-11.

26. Chen MY, Hua YJ, Wan XB, et al. A posteriorly pedicled middle turbinate mucoperiosteal flap resurfacing nasopharynx after endoscopic nasopharyngectomy for recurrent nasopharyngeal carcinoma. Otolaryngol Head Neck Surg. 2012 Mar; 146(3):409-11. Epub 2012 Jan 6. (In English)

27. Yi-Jun Hua, Ming-Yuan Chen, Chao-Nan Qian, Ming-Huang Hong, Chong Zhao, Ling Guo, Xiang Guo,Kao-jia Cao. Postradiation Nasopharyngeal Necrosis in the Patients with Nasopharyngeal Carcinoma. Head & Neck. 2009,6(31): 807-812 (in English)

28. Yi-Jun Hua, Shu Yu, Ming-Huang Hong，Xiao-Wei Yang, Fang Qiu, Ling Guo, Pei-Yu Huang,Guo-Yi Zhang. Application of Support Vector Machine to predict 5-Year Survival Status of Patients with Nasopharyngeal Carcinoma after Treatment. The Chinese-German journal of clinical oncology. 2006.5:8-12 (in English)

29. Yi-Jun Hua, Ming Huang Hong, Chong Zhao, et al. Short-term Efficacy of Endoscopy-guided Debridement on Radiation-related Nasopharyngeal Necrosis in 20 Nasopharyngeal Carcinoma Patients after Radiotherapy. The Chinese Journal of Cancer, 2008，27（7）734-738 (in English)

30. Hua YJ, Hong MH, Guo L, Chen QY, Xiang YQ, Huang PY.  The Application of Artificial Neural Network to Prediction of 5-year Survival in Nasopharygeal Carcinoma.  Journal of Oncoloy (Chinese) 2006; 12(4): 300-304. (in Chinese)

31. Ming-Yuan Chen, MD, PhD; Wei-Ping Wen, MD, PhD; Xiang Guo, MD, PhD; An-Kui Yang, MD;Chao-Nan Qian, MD, PhD; Yi-Jun Hua, MD; Xiang-Bo Wan, MD; Zhu-Ming Guo, MD;Tian-Ying Li, MD; Ming-Huang Hong, MD. Endoscopic Nasopharyngectomy for Locally Recurrent Nasopharyngeal Carcinoma. The Laryngoscope. 2009, 119(3):516-22 (in English)

32. Hua YJ, Hong MH. Shared decision-making. Evidence based Medicine (Chinese).2005, 5(2):110-112 (in Chinese)

33. Hua YJ, Hong MH, Luo DH, et al. Multivariable Analysis of Prognostic Predictors of 406 Patients with Nasopharyngeal Carcinoma. Chinese Journal of Clinical Oncology, 2005,32（8）: 435－438 (in Chinese)

34. Hua YJ, Hong MH. Advancements of stratal therapy for the Primary Diagnosed Nasopharyngeal Carcinoma. China Cancer，2006，15（12）：804-807 (in Chinese)

35. Hua YJ, Hong MH. The application of artificial neural networks in medicine. The Journal of Practical Medicine. 2005, 21（3）: 330－332 (in Chinese)

更新时间：2024.04.29